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Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML)
after allogeneic stem cell transplantation (alloSCT). Leukemia resistance and secondary graft-versus-host
disease (GVHD) are major obstacles to success with DLI. The aim of this study was to identify pre-DLI
factors associated with prolonged survival in remission without secondary GVHD. We retrospectively
analyzed 500 patients treated with DLI for CML relapse (16% molecular, 30% cytogenetic, and 54% he-
matological) after alloSCT. The overall probabilities of failure- and secondary GVHDefree survival (FGFS)
were 29% and 27% at 5 and 10 years after DLI, respectively. The type of relapse was the major factor
inﬂuencing FGFS (40% for molecular and/or cytogenetic relapse and 20% for hematological relapse at 5
years, P < .001). Chronic GVHD before DLI and an interval <1 year between alloSCT and ﬁrst DLI were
independently associated with inferior FGFS in patients with molecular and/or cytogenetic relapse.
Consequently, FGFS was 13%, 35%, to 56% at 5 years in patients with 2, 1, and 0 adverse features,
respectively. In patients with hematological relapse, independent adverse prognostic factors for FGFS
were initial dose of CD3þ cells  50  106/kg, donor-recipient sex mismatch, and chronic GVHD before
DLI. FGFS was 0%, 17%, 33%, to 37% in patients with 3, 2, 1, and 0 adverse features, respectively. The
probability of survival in remission without secondary GVHD was highest (>50% at 5 years) when DLI
were given beyond 1 year from alloSCT for molecular and/or cytogenetic CML relapse that was not
preceded by chronic GVHD.
 2015 American Society for Blood and Marrow Transplantation.edgments on page 1235.
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ty for Blood and Marrow Transplantation.INTRODUCTION
Despite the introduction of imatinib and other tyrosine
kinase inhibitors (TKI), allogeneic stem cell transplantation
(alloSCT) remains an important treatment option for chronic
A. Radujkovic et al. / Biol Blood Marrow Transplant 21 (2015) 1230e1236 1231myeloid leukemia (CML) patients who do not respond
adequately to TKI therapy [1]. Currently, alloSCT is recom-
mended for eligible patients in advanced-phase CML and in
instances of failure of and/or intolerance toTKI treatment [2].
Because of advances in supportive care and improvement of
conditioning regimens, relapse of the original malignancy
has become themost common cause of treatment failure and
mortality after alloSCT [3].
Treatment with donor lymphocyte infusions (DLI) repre-
sents 1 of the most established therapeutic approaches to
post-allograft relapse and has radically changed the prog-
nosis of CML patients relapsing after alloSCT [4,5]. Responses
achieved after DLI in relapsed CML are frequently durable,
offering potential cure for the majority of patients [6-8]. CML
relapse may be diagnosed at the molecular, cytogenetic, and
hematological level, resulting in extreme heterogeneity of
patient and disease status when treatment with DLI is
applied [9-11]. This is evenmore complex nowadayswith the
availability of TKI, capable of restoring complete molecular
remission (CMR) after relapse [12-14].
Major obstacles to success with DLI are represented by
leukemia resistance and by the induction of graft-versus-
host disease by the infused lymphocytes (secondary
GVHD), the latter representing the most threatening side-
effect of DLI treatment [4]. Response to DLI, incidence of
secondary GVHD, and outcome of patients developing sec-
ondary GVHD have been reported in previous studies by the
Chronic Malignancies Working Party of the European Group
for Blood and Marrow Transplantation (EBMT) [15-17].
Occurring in up to 40% of patients, secondary GVHD was
shown to be associatedwith a 2.3-fold increased risk of death
compared with patients without secondary GVHD [17]. With
regard to the availability of TKI, additional treatment mo-
dalities are available for preventing and treating relapse after
alloSCT. However, since alloSCT is increasingly performed in
TKI-resistant patients, DLI is an attractive and important
treatment modality, especially if the resistant clone persists.
It is evident that the best result is obtained when a patient
treated with DLI achieves a durable molecular remission
without experiencing secondary GVHD. In fact, CML
response to DLI is frequently, but not always, separated from
secondary GVHD, suggesting that the graft-versus-leukemia
effect (GVL) may be independent of the development of
secondary GVHD [6,9,16,18]. However, it remains unclear
what the proportion of such patients is and which factors
may predict for such a favorable outcome when DLI are
administered for CML relapsing after alloSCT. The aim of this
study was, therefore, to identify pre-DLI factors associated
with probability of survival in remission without secondary
GVHD. The information may be used to determine when
treatment for CML relapse with DLI can be “optimal” (ie, high
chance of achieving a prolonged survival and a durable
remission without experiencing secondary GVHD).
PATIENTS AND METHODS
This study was based on the registry of the EBMT and conducted within
the Chronic Malignancies Working Party. The study was approved by the
review board of the Chronic Malignancies Working Party. EBMT member
centers were asked to report and update their experience with patients
treated with unmanipulated DLI for recurrent CML after the ﬁrst alloSCT
from an HLA-identical sibling or an HLA-matched volunteer unrelated
donor. The reports included adequate information collected on disease
response, secondary GVHD, and survival after DLI.
Lymphocytes were collected from the donors by apheresis on 1 or more
occasions and administered as single or multiple infusions. Infusions given
on multiple days had to be at least 7 days apart to be counted as separate
infusions. The phase of CML was classiﬁed in accordance with the criteriaproposed by the Center for International Blood and Marrow Transplant
Research [19]. Relapse was classiﬁed as molecular, cytogenetic, or hemato-
logical in accordance with previous reports [16,17]. Patients treated with DLI
for CML relapse in blast crisis were excluded. Relapse stage at DLI was
deﬁned asmolecular, cytogenetic, and hematological assessed on the date of
ﬁrst DLI infusion after relapse or closest date before this infusion. Acute and
chronic GVHD occurring after DLI was reported according to the standard
clinical criteria and in accordance with previous reports [16,17]. A total of
500 patients treated with DLI for CML relapse at 68 EBMT centers between
1988 and 2004 had complete data for analysis. None of the patients had
received imatinib before transplantation. All patients received DLI for
relapse of CML after alloSCT in absence of GVHD and/or its treatment.
Survival was calculated from the date of the ﬁrst infusion of donor
lymphocytes until death or last follow-up evaluation. Failure-free survival
(FFS) was calculated from the date of the ﬁrst infusion of donor lymphocytes
until death, last follow-up evaluation, or occurrence of an event such as
unresponsiveness to DLI or relapse after response to DLI. Failure- and sec-
ondary GVHDefree survival (FGFS) was calculated from the date of the ﬁrst
infusion of donor lymphocytes until death, last follow-up evaluation, or
occurrence of an event, such as unresponsiveness to DLI, relapse after
response to DLI, or secondary GVHD.
Survival curves were calculated according to the method of Kaplan and
Meier; the log-rank test was used to compare survival curves; a proportional
hazard regression model (Cox model) was used for survival probabilities
[20]. We studied the following possible risk factors (categorization criteria):
patient gender (0 ¼male, 1 ¼ female), patient age at DLI (0 ¼ <40 years, 1 ¼
40 years), donor type (0 ¼ HLA-identical sibling, 1 ¼ unrelated), donor
gender (0 ¼male, 1 ¼ female), sex mismatch with the donor (0 ¼matched,
1 ¼ mismatched, ie, female donor/male recipient and male donor/female
recipient), phase at alloSCT (0 ¼ ﬁrst chronic phase [CP1], 1 ¼ beyond CP1),
stem cell source (0 ¼ bone marrow, 1 ¼ peripheral blood), total body irra-
diation in the conditioning regimen (0 ¼ no, 1 ¼ yes), T cell depletion (0 ¼
no, 1 ¼ yes), acute GVHD before DLI (0 ¼ no, 1 ¼ yes), chronic GVHD before
DLI (0 ¼ no, 1 ¼ yes), interval from alloSCT to DLI (0 ¼ 1 year, 1 ¼ <1 year),
type of relapse (0¼molecular and/or cytogenetic, 1¼ hematological), initial
cell dose (ie, donor CD3þ cells/kg recipient body weight of ﬁrst transfusion)
(0 ¼ <median value, 1 ¼ median value). Factors signiﬁcantly associated
with shorter FGFS in univariate analysis were tested for their predictive
value on FGFS in multivariate Cox regression models. Hazard ratios were
estimated with 95% conﬁdence interval (95% CI). Values of P < .05 were
considered statistically signiﬁcant.
RESULTS
Patient Characteristics
Fifty-nine percent of patients were males and the median
patient age at time of DLI was 39 (range, 4 to 64) years with
15% older than 50 years. The donor was an HLA-identical
sibling in 73% and unrelated in 27%. The donor was female
in 37% of the cases and 44% of patients were sex mismatched
with the donor. AlloSCTwas performed in CP1 in 410 patients
(82%), whereas 89 (18%) underwent transplantation in more
advanced phases of the disease. Stem cell source was bone
marrow in 408 (86%), peripheral blood in 64 (14%), and in-
formation was not available in 28 patients. All patients were
conditioned with a standard regimen, including total body
irradiation in 77% of the cases. GVHD prophylactic measures
included in vivo T cell depletion in 241 patients (51%). A total
of 316 patients (69%) had GVHD before relapse: 124 acute
GVHD only, 66 chronic GVHD only, 114 acute and chronic
GVHD, and 12 GVHD unclassiﬁed. Median follow-up time of
surviving patients was 56 months (range, 1 to 168).
DLI Characteristics
DLI was started at a median interval of 23 months from
alloSCT (range, 1 to 146 months) in 132 patients (26%) within
12 months from alloSCT. Relapse type was molecular in 80
(16%), cytogenetic in 150 (30%), and hematological in 270
(54%) cases. DLI was started with a cell dose of 20  106
CD3þ cells/kg recipient body weight in 62% of patients; 207
patients (41%) received 2 or more additional infusions of
donor cells. Cumulative cell dose ranged from 1105 to 1.4
109 CD3þ cells/kg recipient body weight (median, 70  106
Figure 2. FFS (A) and FGFS (B) in 500 patients treated with DLI for relapse of
CML after alloSCT according to the type of relapse (molecular and/or cytoge-
netic relapse, n ¼ 230; hematological relapse, n ¼ 270). (A) Probability of FFS
at 5 years after DLI was 71% in molecular and/or cytogenetic relapses and 46%
in hematological relapses (P < .001). (B) Probability FGFS at 5 years after DLI
was 40% in molecular and/or cytogenetic relapses and 20% in hematological
relapses (P < .001).
A. Radujkovic et al. / Biol Blood Marrow Transplant 21 (2015) 1230e12361232CD3þ cells/kg recipient body weight). Data on donor
chimerismwere available in a total of 44 patients. At the time
of DLI, a total of 11 patients were taking immunosuppressive
medication (ie, cyclosporine A). A total of 27 patients (5%)
received concomitant imatinib therapy with DLI.
Outcome
After DLI administration, response to DLI was assessed in
a total of 480 patients (20 patients had missing information).
Cytogenetic complete remission and/or CMR were achieved
in 341 patients (71%) in a median of 7.5 months (within 41
months in 95% of the cases) from ﬁrst DLI. The median
duration of response was 35 (range, 0 to 150) months. A total
of 139 patients showed no response after DLI treatment.
Twenty-three patients experienced a recurrence at a median
of 11 months from the maximal response (range, 2 to 38).
A total of 222 (44%) patients developed secondary GVHD a
median of 3 (range, .2 to 77) months from ﬁrst DLI (within 32
months in 95% of the cases). Secondary acute GVHD occurred
in 191 (38%) patients at a median of 2 (range, .2 to 42)
months after ﬁrst DLI (within 29 months in 95% of the cases)
with 61, 70, 40, and 20 patients being diagnosed with sec-
ondary acute GVHD grade 1, 2, 3, and 4, respectively. Sec-
ondary chronic GVHD occurred in 87 (17%) patients (limited
and extensive chronic GVHD in 50 and 37 patients, respec-
tively) at a median of 7 (range, 1 to 77) months after ﬁrst DLI
(within 41 months in 95% of the cases). A total of 29 patients
experienced secondary chronic GVHD without preceding
secondary acute GVHD.
Estimated probability of survival was 64% (95% CI, 62% to
66%) and 59% (95% CI, 56% to 62%) at 5 and 10 years after DLI,
respectively. Estimated probability of FFS was 57% (95% CI,
55% to 59%) and 54% (95% CI, 51% to 57%) at 5 and 10 years
after DLI, respectively. Estimated probability of FGFS was 29%
(95% CI, 27% to 31%) and 27% (95% CI, 24% to 30%) at 5 and 10
years after DLI, respectively (Figure 1).
For the purpose of this analysis, patients treated in mo-
lecular relapse and those treated in cytogenetic relapse were
grouped together because they had similar FFS (68% and 73%
at 5 years after DLI, respectively, P ¼ .50) and FGFS (40% and
39% at 5 years after DLI, respectively, P ¼ .80). Estimated
probability of FFS at 5 years after DLI was 71% in molecular
and/or cytogenetic relapses and 46% in hematological re-
lapses (P< .001) (Figure 2A). Estimated probability of FGFS at
5 years after DLI was 40% in molecular and/or cytogenetic
relapses and 20% in hematological relapses (P < .001)
(Figure 2B). It should be noted that for the purpose of thisFigure 1. Overall survival, FFS, and FGFS in 500 patients treated with DLI for
relapse of CML after alloSCT. Probability of survival at 5 and 10 years after DLI
was 64% (95% CI, 62% to 66%) and 59% (95% CI, 56% to 62%), respectively.
Probability of FFS was 57% (95% CI, 55% to 59%) and 54% (95% CI, 51% to 57%) at
5 and 10 years after DLI, respectively. Probability of FGFS was 29% (95% CI, 27%
to 31%) and 27% (95% CI, 24% to 30%) at 5 and 10 years after DLI, respectively.study, secondary acute and chronic GVHD of all severity
grades were considered in the composite endpoint of FGFS.
Because type of relapse was a major factor inﬂuencing FGFS,
prognostic factors were analyzed separately, according to the
type of relapse.Molecular and/or Cytogenetic Relapse
Univariate analysis showed that 3 factors (ie, donor type,
chronic GVHD before relapse, and interval from alloSCT to
DLI) were signiﬁcantly correlated to FGFS from DLI (Table 1).
Multivariate analysis showed that interval from SCT to DLI
<1 year (hazard ratio [HR], 2.2; 95% CI, 1.5 to 3.2; P < .001)
and a history of chronic GVHD before DLI (HR, 1.8; 95% CI, 1.3
to 2.5; P ¼ .001) were independent adverse prognostic fac-
tors for FGFS (Table 2A). Forty-three percent, 44%, and 13% of
patients had 0, 1, and 2 adverse features, respectively.
Consequently, FGFS at 5 years was 13%, to 35%, and 56% in
patients with 2, 1, and 0 adverse features, respectively (P <
.001) (Figure 3A).Hematological Relapse
Univariate analysis showed that 6 factors (ie, donor
gender, sex mismatch with the donor, phase at alloSCT,
chronic GVHD before relapse, interval from alloSCT to DLI,
Table 1
Clinical Features and FGFS in 500 Patients Treated with DLI for CML Relapsing after alloSCT According to the Type of Relapse (Univariate Analysis)
Clinical Features Molecular and/or Cytogenetic Relapse Hematological Relapse
Year of DLI, median (range) 1999 (1990-2004) 1996 (1988-2002)
Total No. Total % FGFS % at 5 Years P Value Total No. Total % FGFS % at 5 Years P Value
Patient gender
Male 125 54 38 .95 169 63 21 .56
Female 105 46 41 101 37 18
Patient age
<40 yr 115 50 40 .71 149 55 22 .14
40 yr 115 50 39 120 45 16
NA 0 1
Donor type
HLA-identical sibling 157 68 45 .02 207 77 21 .30
Unrelated 73 32 29 63 23 16
Donor gender
Male 139 61 37 .78 174 65 23 .04
Female 89 39 43 92 35 14
NA 2 4
Donor-recipient sex Match
Matched 128 56 42 .19 148 56 23 .03
Mismatched 100 44 35 118 44 16
NA 2 4
CML phase at alloSCT
CP1 202 88 41 .22 208 77 23 .03
Beyond CP1 27 12 29 62 23 8
NA 1
Stem cell source
BM 176 82 40 .50 232 90 24 .67
PB 38 18 43 26 10 14
NA 16 12
TBI
No 53 23 37 .88 62 23 20 .98
Yes 174 77 41 204 77 20
NA 3 4
T cell depleted
No 94 43 42 .38 139 54 19 .36
Yes 123 57 36 118 46 19
NA 13 13
Acute GVHD before DLI
No 109 48 38 .35 134 50 23 .54
Yes 116 52 43 132 50 17
NA 5 4
Chronic GVHD before DLI
No 130 59 49 .003 156 63 26 .02
Yes 89 41 29 93 37 13
NA 11 21
Time from alloSCT to DLI
1 yr 160 70 48 <.001 207 77 22 .02
<1 yr 70 30 21 62 23 11
NA 0 1
Initial cell dose
<Median* 78 39 43 .88 87 51 30 .003
Median 120 61 43 82 49 18
NA 32 101
Total 230 100 40 270 100 20
NA indicates not assessed; BM, bone marrow; PB, peripheral blood; TBI, total body irradiation.
* Median value was of 10  106 CD3þ cells/kg in patients with molecular and/or cytogenetic relapse, and of 50  106 CD3þ cells/kg in patients with he-
matological relapse.
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from DLI (Table 1).
Multivariate analysis showed that sex mismatch with the
donor (HR, 1.6; 95% CI, 1.1 to 2.4, P ¼ .01), a history of chronic
GVHD before DLI (HR, 1.7; 95% CI, 1.2 to 2.5, P ¼ .006), and an
initial cell dose 50  106/kg (HR, 1.8; 95% CI, 1.2 to 2.7, P ¼
.002) were independent adverse prognostic factors for FGFS
(Table 2B). Seventeen percent, 40%, 33%, and 9% of patients
had 0, 1, 2, and 3 adverse features, respectively. Survival in
remission without secondary GVHD at 5 years was 0%, 17%,
33%, and 37% in patients with 3, 2, 1, and 0 adverse features,
respectively (P < .001) (Figure 3B).DISCUSSION
Response of CML to DLI is sometimes, but not always,
accompanied by secondary GVHD that may be fatal in some
cases. With escalating dose regimens, responses could be
achieved without secondary GVHD and such outcome was
not infrequent, particularly when DLI were given to treat
molecular and/or cytogenetic relapse [16,21,22]. However,
measures of such a phenomenon and factors associated with
such positive outcomes have not yet been provided by pre-
vious studies. We retrospectively studied a large population
of 500 patients treated with DLI for CML relapsing after
alloSCT. Overall FFS and FGFS survival curves show that
Table 2
Cox Regression Analysis of Prognostic Factors for FGFS after DLI in Patients
with Molecular and/or Cytogenetic CML Relapse and Patients with Hema-
tological CML Relapse (Multivariate Analysis)
A. Molecular and/or Cytogenetic CML Relapse
Parameter HR 95% CI P Value
Donor type
HLA-identical sibling 1
Unrelated 1.2 .8-1.7 .42
Chronic GVHD before DLI
No 1
Yes 1.8 1.3-2.5 .001
Time from alloSCT to DLI
1 yr 1
<1 yr 2.2 1.5-3.2 <.001
B. Hematological CML Relapse
Parameter HR 95% CI P Value
Donor gender
Male 1
Female 1.3 .9-2.0 .14
Donor-recipient sex match
Matched 1
Mismatched 1.6 1.1-2.4 .01
CML phase at alloSCT
CP1 1
Beyond CP1 1.1 .7-1.7 .77
Chronic GVHD before DLI
No 1
Yes 1.7 1.2-2.5 .006
Time from alloSCT to DLI
1 yr 1
<1 yr 1.0 .6-1.7 .87
Initial cell dose
<50  106/kg 1
50  106/kg 1.8 1.2-2.7 .002
Figure 3. FGFS according to the cumulative number of adverse features in
patients treated with DLI for molecular and/or cytogenetic CML relapse (n ¼
219) (A) and in patients treated with DLI for hematological CML relapse (n ¼
156) (B) after alloSCT. (A) Ninety-four (43%), 97 (44%), and 28 (13%) patients
showed 0, 1, and 2 adverse features (ie, chronic GVHD before relapse, and
interval from alloSCT to DLI <1 year), respectively. FGFS at 5 years was 13%,
35%, and 56% in patients with 2, 1, and 0 adverse features, respectively (P <
.001). (B) Twenty-seven (17%), 63 (40%), 52 (33%), and 14 (9%) patients had 0, 1,
2, and 3 adverse features (ie, sex mismatch with the donor, chronic GVHD
before relapse, and initial cell dose  50  106 CD3þ cells/kg), respectively.
FGFS at 5 years was 0%, 17%, 33%, and 37% in patients with 3, 2, 1, and 0 adverse
features, respectively (P < .001).
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GVHD after DLI. The type of relapse was the major factor
inﬂuencing such an outcome, with patients in molecular
and/or cytogenetic relapse doing far better than patients in
hematological relapse. Thus, and with regard to the differing
treatment periods, our analysis was conducted separately in
the 2 groups according to type of relapse: molecular and/or
cytogenetic relapse (230 patients) and hematological relapse
(270 patients).
Our univariate analyses revealed that in both types of
relapse, prior chronic GVHD and a shorter interval between
alloSCT and ﬁrst DLI were signiﬁcantly associated with
inferior FGFS. For patients relapsed at the molecular and/or
cytogenetic level both factors independently predicted a 2-
fold increased risk of treatment failure and secondary GVHD
in multivariate analysis. Consequently, estimated leukemia-
free survival in absence of secondary GVHD was signiﬁ-
cantly improved, reaching 56% at 5 years when DLI were
given beyond 1 year from alloSCT for a molecular and/or
cytogenetic CML relapse that was not preceded by chronic
GVHD. For patients with hematological CML relapse, besides
occurrence of chronic GVHD before relapse, sex mismatch
with the donor and an initial cell dose 50 106 CD3þ cells/
kg were conﬁrmed as independent prognostic factors pre-
dicting worse FGFS. When stratiﬁed according to the cu-
mulative number of these 3 adverse pre-DLI factors, survival
in remissionwithout secondary GVHD decreased from 37% to
0% at 5 years in patients presenting with no and all 3 adverse
features, respectively.
Previous studies show that advanced stage of CML relapse
was a major factor predicting leukemia-free survival after
DLI without inﬂuencing secondary GVHD incidence orDLI-related mortality [16,23]. Conﬁrming the impact of
relapse stage on failure-free survival, in our study the “pure
GVL” effect (durable remission after DLI treatment in absence
of secondary GVHD) could be similarly observed in nearly one
half of the responding patients receiving DLI for any type of
CML relapse. We are aware that the expression “pure GVL” is
not established. But given the current limitations in sepa-
rating GVL from GVHD, we believe that it may be used to
characterize outcomes when regarding the composite
endpoint of FGFS in our study. Early relapse after alloSCT has
been shown to be a risk factor predicting worse treatment
response and survival in patients treated with DLI [16,24]. In
addition, a longer interval between alloSCT and ﬁrst DLI was
associated with less secondary GVHD in several studies
[15,17,24]. Although controversial, some form of tolerance
induced by the previous transplantation, of which the exact
mechanisms remain to be identiﬁed, was suggested for this
observation [17]. Because relapse type is amajor risk factor for
treatment failure but not for secondary GVHD, factors
affecting both treatment response and secondary GVHD
incidence may be of higher prognostic relevance in patients
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study, a shorter interval between alloSCT and ﬁrst DLI (<1
year) was associated with worse FGFS in patients with mo-
lecular and/or cytogenetic relapse but not in patients with
hematological CML relapse. In a previous study, sexmismatch
with the donor and higher cell dose at ﬁrst DLI resulted in
similar response rates but greater secondary GVHD incidence
and increased DLI-related mortality, leading to reduced
overall survival [16]. In the present study, both factors
emerged as independent predictors of worse FGFS in patients
with hematological CML relapse. However, it is important to
note that in themolecular and/or cytogenetic subgroup, there
was no correlation between the initial cell dose and FGFS.
The correlation between increasing initial CD3þ cell dose
and incidence of secondary GVHD has been well reported
[16,17,21,24]. In addition, CML disease stage at relapse was
demonstrated to be a major factor inﬂuencing the effective
cell dose (ie, CD3þ cell dose required to achieve remission),
suggesting that although DLI treatment is highly effective
even at lower cell doses, the larger the tumor burden, the
greater the number of cells required to restore remission
[25]. In our study, the median initial CD3þ cell dose was
lower in patients treated for molecular and/or cytogenetic
relapse compared with those treated for hematological
relapse. Therefore, it could be that relapse rates were higher
at the lower initial dose, and so the composite endpoint of
FGFS in our study washes out the difference. Furthermore, it
has to be mentioned that for the parameter sex mismatch
with the donor all mismatched donor-recipient sex combi-
nations were included, which is analogous with the previous
study [16]. Although Y-chromosome minor antigens are
known to contribute to the allo-reactive immunogenicity in
male recipients from female donors, in our study, the
constellation female donor/male recipient was not associ-
ated with shorter FGFS compared with other donor-recipient
combinations.
Our study of 500 CML patients revealed that, regardless of
the relapse type, occurrence of chronic GVHD after trans-
plantation and before relapse was a major factor predicting
worse FGFS after DLI. This is in contrast to previous reports
by Raiola et al. [23] and Bar et al. [24] demonstrating no
impact of prior chronic GVHD on secondary GVHD incidence,
treatment response, and overall mortality after DLI treat-
ment in 100 CML patients and 225 patients with different
hematological malignancies, respectively. In addition to a
larger patient number, another reason for our observation is
probably the composite endpoint of FGFS used in our study.
The potential impact of prior chronic GVHD on increasing
risk of treatment failure and/or increasing risk of subsequent
GVHD could then be explained, as both risks contribute
additively to shorter FGFS.
It is obvious that this study has several limitations
including its retrospective nature, multicentric approach,
and the treatment period addressed. Consequently, the ma-
jority of patients in our study received bone marrow trans-
plantation, which is different from the current practice. In
addition, the median follow-up at the time of the analysis
was 56 months, which may be too short to assess late
occurring events, such as chronic GVHD, that may develop
many years after DLI. Furthermore, although the patients
evaluated in our study received DLI in absence of any GVHD
and/or its treatment, it is important to note that GVHD
developing after DLI administration may be de novo, but in
patients who had experienced GVHD before relapse, it may
also represent reactivation of a pre-existing GVHD.Data on the comparison between TKI and DLI are limited
and the exact role of TKI in the treatment of post-allograft
relapse in CML remains to be deﬁned. In an early study by
Weisser et al. [26], DLI was superior to treatment with ima-
tinib in terms of leukemia-free survival, suggesting that TKI
alone might not provide deﬁnite cure for relapsed CML after
alloSCT. In contrast, a more recent report demonstrated that
imatinib treatment resulted in higher overall and disease-
free survival compared with those after DLI [27]. Moreover,
concomitant use of imatinib was not associated with an
increased risk of secondary GVHD [17], and in a small series,
imatinib was shown to synergize with DLI to achieve rapid
CMR of CML relapsing after alloSCT [28]. Unfortunately, in
our study the number of patients on concomitant TKI treat-
ment was very low; thus, precluding further analysis in the
context of the pre-DLI factors identiﬁed.
Nevertheless, our data might prove extremely important
when deciding the best therapy for CML relapse after alloSCT.
Although there is clearly a lack of reliable data on the use of
TKI for the treatment of relapse, many centers are utilizing
imatinib or second generation TKIs (dasatinib or nilotinib)
for these patients. The advantages of TKI are the low inci-
dence of secondary GHVD (including patients with prior
GHVD), the relatively low toxicity proﬁle (apart from he-
matological toxicity), and the signiﬁcant response rate
[29,30]. The disadvantages include on and off target side
effects, pancytopenia, the potential for selection of mutant
variants of Bcr-Abl, and the high incidence of relapse if
treatment is withdrawn [3,30].
For a given patient, the presence of relapse at the hema-
tological level, prior GVHD, and an interval from trans-
plantation of less than 1 year may argue in favor of using TKI
(as the probability of FGFS is very low) and for a patient re-
lapsing in molecular or cytogenetic relapse, with no prior
history of GVHD and more than 12 months from the trans-
plantation, the probability of long term FGFS of over 50%
would make the use of DLI the preferred option. Moreover,
similar studies are warranted for other diseases that share a
number of characteristics with CML: chronic, slow type of
relapse after alloSCT, good responses to DLI, evidence of GVL
without GVHD, and the availability of modern targeted
therapies that could be used for the management of relapse
after alloSCT. Examples of these are chronic idiopathic
myeloﬁbrosis and JAK2 inhibitors, such as ruxolitinib,
chronic lymphocytic leukemia and idelalisib/ibrutinib, mul-
tiple myeloma and lenalidomide/bortezomib, and to a lesser
extent, myelodysplastic syndrome and azacitidine/
decitabine.
In conclusion, this study shows that a “pure GVL” effect
was present in approximately one half of responding pa-
tients treated with DLI. The probability of survival in durable
remission without secondary GVHD was higher when DLI
was given at molecular and/or cytogenetic than at hemato-
logical stage of CML relapse. The chances of exploiting the
“pure GVL” effect were best when DLI were given beyond 1
year from alloSCT for molecular and/or cytogenetic CML
relapse that was not preceded by chronic GVHD.
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